stockrow
Friday 6 November 2026
Export BIAF’s income statement to Excel — free account
bioAffinity Technologies, Inc.
BIAF Healthcare Diagnostics & Research
bioAffinity Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 million, down 34.2% from fiscal 2024.
- Revenue
- +19.0%
- EPS
- +87.5%
- Free cash flow
- −23.7%
- Total debt
- +569.7%
Quarter to June 2026, against a year earlier
2.71
0.22
−7.51%
Follow BIAF
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 0 | 3 | 9 | 6 | 6 | +986.8% | 7 | — | — | +18.6% | |
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 89.58 | 31.26 | 36.09 | 31.41 | 34.61 | +31.4 pt | ||||||
| EBT | — | — | — | (3) | (7) | (6) | (8) | (8) | (9) | (15) | (15) | +28.5% | ||||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | (169,827.08) | (312.58) | (96.43) | (241.25) | (257.23) | (241.2) pt | ||||||
| Net income | — | — | — | (3) | (7) | (6) | (8) | (8) | (9) | (15) | (15) | +28.5% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.48 | 130.54 | 346.74 | 53.68 | 16.93 | n/m | |||||
| Earnings | — | — | — | (0.45) | (0.99) | (1,062.53) | (814.91) | (409.70) | (337.67) | (129.83) | (103.32) | +157.1% | ||||||
| Cash flow | — | — | — | (0.34) | (0.30) | (347.29) | (407.08) | (311.23) | (269.07) | (81.26) | (32.90) | +149.4% | ||||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | (22.00) | (1.18) | (2.93) | (0.53) | (0.26) | n/m | ||||||
| Free cash flow | — | — | — | (0.34) | (0.30) | (347.29) | (429.08) | (312.41) | (272.00) | (81.79) | (33.16) | +149.7% | ||||||
| Book value | — | — | — | (0.55) | (1.49) | (2,676.39) | 1,104.34 | 250.27 | 96.37 | 63.39 | 10.81 | n/m | ||||||
| Shares, m | — | — | — | 7 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | (50.0%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | 0.00 | 5.83 | 1.18 | 0.33 | 0.16 | 1.8 | ||||||
| P/B | — | — | — | — | — | — | 0.64 | 3.04 | 4.25 | 0.28 | 0.25 | 2.1 | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 5.22 | 1.13 | (0.61) | (0.16) | 1.4 | ||||||
| EV/FCF | — | — | — | — | — | — | 1.02 | (2.18) | (1.44) | 0.40 | 0.08 | (0.6) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (2) | (2) | (2) | (4) | (6) | (7) | (9) | (11) | +24.6% | |||||
| Capex | — | — | — | 0 | 0 | — | 0 | 0 | 0 | 0 | 0 | +32.1% | ||||||
| Free cash flow | — | — | — | (2) | (2) | (2) | (4) | (6) | (7) | (9) | (12) | +24.8% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | (4) | (11) | (12) | 11 | 2 | 0 | 5 | 1 | n/m | |||||
| Net debt | — | — | — | 3 | 10 | 10 | (11) | (2) | 0 | (6) | (2) | n/m | ||||||
| Shareholders’ equity | — | — | — | (4) | (11) | (16) | 11 | 5 | 3 | 7 | 4 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (1,807.24) | (791.34) | (119.60) | (77.80) | (122.70) | (170.65) | (245.51) | (170.6) pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (173.68) | (262.35) | (438.42) | (408.67) | (438.4) pt | ||||||
| ROE | — | — | — | 0.00 | 62.79 | 41.00 | 343.53 | (99.84) | (242.44) | (301.83) | (1,860.15) | (301.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 14 | 14 | 75 | 57 | 57 | — | +42.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.03 | 0.16 | 0.11 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
bioAffinity Technologies, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| NDRA ENDRA Life Sciences Inc. | $7.5M | — (loss-making) | — (loss-making) | −98.80% (below 0%: shrinking) | n/m | +15.04% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TTOO T2 Biosystems, Inc. | $6.5M | — (loss-making) | — (loss-making) | +34.85% (above 0%: growing) | n/m | +53.36% (above 0%: growing) | (106.60%) | (511.89%) | Compare |
| XWEL XWELL, Inc. | $6.1M | — (loss-making) | — (loss-making) | −7.08% (below 0%: shrinking) | n/m | −43.02% (below 0%: shrinking) | 41.26% | (29.45%) | Compare |
| BIAF bioAffinity Technologies, Inc. | $3.3M | — (loss-making) | — (loss-making) | +18.99% (above 0%: growing) | n/m | −23.69% (below 0%: shrinking) | 27.98% | (220.77%) | |
| DMTKQ DermTech, Inc. | $3.3M | — (loss-making) | — (loss-making) | +10.58% (above 0%: growing) | n/m | +24.87% (above 0%: growing) | 18.54% | (533.37%) | Compare |
| ADVB Advanced Biomed Inc. | $3.1M | 0.3× | — | — | n/m | −101.33% (below 0%: shrinking) | — | 0.00% | Compare |
| AWHL Aspira Women's Health Inc. | $2.4M | — (loss-making) | — (loss-making) | −14.89% (below 0%: shrinking) | n/m | −24.57% (below 0%: shrinking) | 55.28% | (89.69%) | Compare |
| ISPC iSpecimen Inc. | $2.0M | — (loss-making) | — (loss-making) | −78.70% (below 0%: shrinking) | n/m | −257.73% (below 0%: shrinking) | 45.23% | (897.30%) | Compare |
| PRPH ProPhase Labs, Inc. | $1.2M | — (loss-making) | — (loss-making) | −18.93% (below 0%: shrinking) | n/m | +56.67% (above 0%: growing) | 22.35% | (261.62%) | Compare |
| Median of peers | $3.2M | — | — | −14.89% | — | −4.76% | 22.35% | (175.65%) |